Wuxi Biologics

WuXi Biologics, headquartered in China and operating in Research and Development in Biotechnology, reported Scope 1 emissions of 44,125,000 kg CO2e, Scope 2 emissions of 185,605,000 kg CO2e, and partial Scope 3 emissions totalling 84,206,000 kg CO2e for the year 2025. This compares to 2024, when the company recorded Scope 1 emissions of 38,346,000 kg CO2e, Scope 2 emissions of 160,308,000 kg CO2e, and partial Scope 3 emissions of 70,064,000 kg CO2e. For 2023, Scope 1 emissions were 32,687,000 kg CO2e, Scope 2 emissions were 149,229,000 kg CO2e, and partial Scope 3 emissions amounted to 65,462,400 kg CO2e.

WuXi Biologics (Cayman) Inc. has set ambitious climate commitments. The company aims to reduce its Scope 1 and Scope 2 GHG emission intensity by 50% (tonnes/RMB10,000) by 2030, using 2020 as a base year. Furthermore, it has near-term Science Based Targets initiative (SBTi) commitments to reduce absolute Scope 1 and Scope 2 GHG emissions by 58.8% by 2034, from a 2024 base year. The company also commits to reducing Scope 3 GHG emissions covering purchased goods and services by 63.8% per kg of product produced within the same timeframe. For the long term, WuXi Biologics (Cayman) Inc. commits to reaching net-zero greenhouse gas emissions across its entire value chain by 2050. This includes reducing absolute Scope 1 and Scope 2 GHG emissions by 90% by 2050 from a 2024 base year, and absolute Scope 3 GHG emissions covering purchased goods and services, capital goods, fuel and energy-related activities, upstream transportation and distribution, waste generated in operations, and employee commuting by 90% within the same timeframe.